3D‐QSAR, molecular docking, and ONIOM studies on the structure–activity relationships and action mechanism of nitrogen‐containing bisphosphonates

Nitrogen‐containing bisphosphonates (N‐BPs) have been used widely to treat various bone diseases by inhibiting the key enzyme farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway. Understanding the structure–activity relationships and the action mechanisms of these bisphosphonates is ins...

Full description

Saved in:
Bibliographic Details
Published inChemical biology & drug design Vol. 91; no. 3; pp. 735 - 746
Main Authors Liu, Qing‐Zhu, Wang, Shan‐Shan, Li, Xi, Zhao, Xue‐Yu, Li, Ke, Lv, Gao‐Chao, Qiu, Ling, Lin, Jian‐Guo
Format Journal Article
LanguageEnglish
Published England 01.03.2018
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Nitrogen‐containing bisphosphonates (N‐BPs) have been used widely to treat various bone diseases by inhibiting the key enzyme farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway. Understanding the structure–activity relationships and the action mechanisms of these bisphosphonates is instructive for the design and the development of novel potent inhibitors. Here, a series of N‐BPs inhibitors of human FPPS (hFPPS) were investigated using a combination of three‐dimensional quantitative structure–activity relationship (3D‐QSAR), molecular docking, and three‐layer ONIOM studies. The constructed 3D‐QSAR model yielded a good correlation between the predicted and experimental activities. Based on the analysis of comparative molecular field analysis (CoMFA) contour maps, a series of novel N‐BPs inhibitors were designed and ten novel potent N‐BPs inhibitor candidates were screened out. Molecular docking and ONIOM (B3LYP/6‐31 + G*:PM6:Amber) calculations revealed that the inhibitors bound to the active site of hFPPS via hydrogen‐bonding interactions, hydrophobic interactions, and cation‐π interactions. Six novel N‐BPs inhibitors with better biological activities and higher lipophilicity were further screened out from ten candidates based on the calculated interaction energy. This study will facilitate the discovery of novel N‐BPs inhibitors with higher activity and selectivity. A 3D‐QSAR model was constructed for 53 N‐BPs with the inhibition activities on hFPPS. A series of novel N‐BPs inhibitors were designed and six novel N‐BPs inhibitors with better biological activities and higher lipophilicity were screened out. Molecular docking and ONIOM (B3LYP/6‐31 + G*:PM6:Amber) calculations showed that the inhibitors bound to the active site of hFPPS via hydrogen‐bonding interactions, hydrophobic interactions, and cation‐π interactions.
AbstractList Nitrogen-containing bisphosphonates (N-BPs) have been used widely to treat various bone diseases by inhibiting the key enzyme farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway. Understanding the structure-activity relationships and the action mechanisms of these bisphosphonates is instructive for the design and the development of novel potent inhibitors. Here, a series of N-BPs inhibitors of human FPPS (hFPPS) were investigated using a combination of three-dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking, and three-layer ONIOM studies. The constructed 3D-QSAR model yielded a good correlation between the predicted and experimental activities. Based on the analysis of comparative molecular field analysis (CoMFA) contour maps, a series of novel N-BPs inhibitors were designed and ten novel potent N-BPs inhibitor candidates were screened out. Molecular docking and ONIOM (B3LYP/6-31 + G*:PM6:Amber) calculations revealed that the inhibitors bound to the active site of hFPPS via hydrogen-bonding interactions, hydrophobic interactions, and cation-π interactions. Six novel N-BPs inhibitors with better biological activities and higher lipophilicity were further screened out from ten candidates based on the calculated interaction energy. This study will facilitate the discovery of novel N-BPs inhibitors with higher activity and selectivity.Nitrogen-containing bisphosphonates (N-BPs) have been used widely to treat various bone diseases by inhibiting the key enzyme farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway. Understanding the structure-activity relationships and the action mechanisms of these bisphosphonates is instructive for the design and the development of novel potent inhibitors. Here, a series of N-BPs inhibitors of human FPPS (hFPPS) were investigated using a combination of three-dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking, and three-layer ONIOM studies. The constructed 3D-QSAR model yielded a good correlation between the predicted and experimental activities. Based on the analysis of comparative molecular field analysis (CoMFA) contour maps, a series of novel N-BPs inhibitors were designed and ten novel potent N-BPs inhibitor candidates were screened out. Molecular docking and ONIOM (B3LYP/6-31 + G*:PM6:Amber) calculations revealed that the inhibitors bound to the active site of hFPPS via hydrogen-bonding interactions, hydrophobic interactions, and cation-π interactions. Six novel N-BPs inhibitors with better biological activities and higher lipophilicity were further screened out from ten candidates based on the calculated interaction energy. This study will facilitate the discovery of novel N-BPs inhibitors with higher activity and selectivity.
Nitrogen‐containing bisphosphonates (N‐BPs) have been used widely to treat various bone diseases by inhibiting the key enzyme farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway. Understanding the structure–activity relationships and the action mechanisms of these bisphosphonates is instructive for the design and the development of novel potent inhibitors. Here, a series of N‐BPs inhibitors of human FPPS (hFPPS) were investigated using a combination of three‐dimensional quantitative structure–activity relationship (3D‐QSAR), molecular docking, and three‐layer ONIOM studies. The constructed 3D‐QSAR model yielded a good correlation between the predicted and experimental activities. Based on the analysis of comparative molecular field analysis (CoMFA) contour maps, a series of novel N‐BPs inhibitors were designed and ten novel potent N‐BPs inhibitor candidates were screened out. Molecular docking and ONIOM (B3LYP/6‐31 + G*:PM6:Amber) calculations revealed that the inhibitors bound to the active site of hFPPS via hydrogen‐bonding interactions, hydrophobic interactions, and cation‐π interactions. Six novel N‐BPs inhibitors with better biological activities and higher lipophilicity were further screened out from ten candidates based on the calculated interaction energy. This study will facilitate the discovery of novel N‐BPs inhibitors with higher activity and selectivity. A 3D‐QSAR model was constructed for 53 N‐BPs with the inhibition activities on hFPPS. A series of novel N‐BPs inhibitors were designed and six novel N‐BPs inhibitors with better biological activities and higher lipophilicity were screened out. Molecular docking and ONIOM (B3LYP/6‐31 + G*:PM6:Amber) calculations showed that the inhibitors bound to the active site of hFPPS via hydrogen‐bonding interactions, hydrophobic interactions, and cation‐π interactions.
Nitrogen-containing bisphosphonates (N-BPs) have been used widely to treat various bone diseases by inhibiting the key enzyme farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway. Understanding the structure-activity relationships and the action mechanisms of these bisphosphonates is instructive for the design and the development of novel potent inhibitors. Here, a series of N-BPs inhibitors of human FPPS (hFPPS) were investigated using a combination of three-dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking, and three-layer ONIOM studies. The constructed 3D-QSAR model yielded a good correlation between the predicted and experimental activities. Based on the analysis of comparative molecular field analysis (CoMFA) contour maps, a series of novel N-BPs inhibitors were designed and ten novel potent N-BPs inhibitor candidates were screened out. Molecular docking and ONIOM (B3LYP/6-31 + G*:PM6:Amber) calculations revealed that the inhibitors bound to the active site of hFPPS via hydrogen-bonding interactions, hydrophobic interactions, and cation-π interactions. Six novel N-BPs inhibitors with better biological activities and higher lipophilicity were further screened out from ten candidates based on the calculated interaction energy. This study will facilitate the discovery of novel N-BPs inhibitors with higher activity and selectivity.
Author Qiu, Ling
Lin, Jian‐Guo
Li, Ke
Wang, Shan‐Shan
Liu, Qing‐Zhu
Lv, Gao‐Chao
Zhao, Xue‐Yu
Li, Xi
Author_xml – sequence: 1
  givenname: Qing‐Zhu
  surname: Liu
  fullname: Liu, Qing‐Zhu
  organization: Jiangsu Institute of Nuclear Medicine
– sequence: 2
  givenname: Shan‐Shan
  surname: Wang
  fullname: Wang, Shan‐Shan
  organization: Jiangnan University
– sequence: 3
  givenname: Xi
  surname: Li
  fullname: Li, Xi
  organization: Jiangnan University
– sequence: 4
  givenname: Xue‐Yu
  surname: Zhao
  fullname: Zhao, Xue‐Yu
  organization: Jiangnan University
– sequence: 5
  givenname: Ke
  surname: Li
  fullname: Li, Ke
  organization: Jiangsu Institute of Nuclear Medicine
– sequence: 6
  givenname: Gao‐Chao
  surname: Lv
  fullname: Lv, Gao‐Chao
  organization: Jiangsu Institute of Nuclear Medicine
– sequence: 7
  givenname: Ling
  orcidid: 0000-0002-9704-8435
  surname: Qiu
  fullname: Qiu, Ling
  email: qiuling@jsinm.org
  organization: Jiangsu Institute of Nuclear Medicine
– sequence: 8
  givenname: Jian‐Guo
  surname: Lin
  fullname: Lin, Jian‐Guo
  email: linjianguo@jsinm.org
  organization: Jiangsu Institute of Nuclear Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29080272$$D View this record in MEDLINE/PubMed
BookMark eNp9kc9uEzEQxi1U1P-XPgDyEaGm2Lv22jm2CYVKhQjanldee7Yx7NrB9lLl1kdA4sD79UlwktJDhbBkeTzz-2ak-fbQlvMOEDqi5ITm81Y3xpzQkpbsBdqlgokRKSTfeoqF2EF7MX4lhDFeyG20U4yJzPliF_0upw_3Pz9fnX45xr3vQA-dCth4_c2622OsnMGzTxezjzimwViI2Duc5pC_YdBpCPBw_0vpZH_YtMQBOpWsd3FuF3GtXZWyogc9V87GHvsWO5uCvwWX52rvkrIuj8KNjYu5X12nEsQD9LJVXYTDx3cf3Zy_u558GF3O3l9MTi9HuuScjaiUgrXUlC03FR83QhRGNxVrjWkrXildSdmQQnHVCqYbxkBAYaQZl5wJ1ZTlPnq96bsI_vsAMdW9jRq6TjnwQ6zpmAsmKy5IRl89okPTg6kXwfYqLOu_y8zAmw2gg48xQPuEUFKvnKpXTtVrpzJMnsHapvX2UlC2-7eEbiR3toPlf5rXk7PpdKP5A-wUqxo
CitedBy_id crossref_primary_10_1016_j_jpba_2023_115371
crossref_primary_10_1016_j_bioorg_2019_103282
crossref_primary_10_1016_j_ejmech_2019_111905
crossref_primary_10_1002_slct_202203319
crossref_primary_10_3390_app8071121
crossref_primary_10_1002_cbin_11546
crossref_primary_10_1186_s12900_018_0095_2
Cites_doi 10.1021/cr5004419
10.1021/jm800325y
10.2174/15701638113106660041
10.1002/jcc.20035
10.1529/biophysj.106.097782
10.1016/S1359-6446(97)01079-9
10.1007/s10822-013-9674-2
10.1016/j.bmc.2012.07.019
10.1021/jp980230o
10.1111/j.1747-0285.2011.01168.x
10.1111/j.1747-0285.2011.01164.x
10.1021/jm058220g
10.1021/acs.jpcb.5b05897
10.1074/jbc.C300511200
10.2174/138161207782794284
10.1021/jm0303709
10.1007/s10522-011-9344-5
10.2174/092986711794088335
10.1021/jm0702884
10.1021/ja00226a005
10.1111/cbdd.12545
10.1021/acs.jmedchem.6b01578
10.1007/s00198-007-0540-8
10.1007/s00894-007-0233-4
10.1038/nrd1364
10.1021/jm7015733
10.1021/jm400946f
10.1111/cbdd.12121
10.1134/S0022476615070124
10.1021/jm010279
10.1021/jm040132t
10.1021/jm030054u
10.4065/84.7.632
10.1016/j.bone.2011.03.774
10.1002/cmdc.200500059
10.1021/ar300265y
10.1126/science.271.5246.163
10.1016/j.bmcl.2008.03.088
10.1021/jm801003y
10.1021/jm201657x
10.1021/ja312656v
10.1016/j.bone.2010.09.035
10.1073/pnas.0601643103
10.1126/science.289.5484.1508
10.1021/jm0302344
10.1002/prot.21123
10.14310/horm.2002.1226
ContentType Journal Article
Copyright 2017 John Wiley & Sons A/S
2017 John Wiley & Sons A/S.
Copyright_xml – notice: 2017 John Wiley & Sons A/S
– notice: 2017 John Wiley & Sons A/S.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1111/cbdd.13134
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
EISSN 1747-0285
EndPage 746
ExternalDocumentID 29080272
10_1111_cbdd_13134
CBDD13134
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: 333 Project of Jiangsu Province
  funderid: BRA2016518
– fundername: National Natural Science Foundation of China
  funderid: 21371082; 21501074
– fundername: Natural Science Foundation of Jiangsu Province
  funderid: BK20141102; BK20151118
– fundername: Key Medical Talent Project of Jiangsu Province
  funderid: QNRC2016626; QNRC2016629
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1OC
29B
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGOF
ACMXC
ACPOU
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EAS
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
EPT
EST
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GODZA
HF~
HGLYW
HVGLF
HZI
IHE
IX1
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK0
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N9A
NDZJH
O66
OIG
OVD
P2W
P4B
P4D
Q.N
Q11
QB0
Q~Q
R.K
RJQFR
ROL
RX1
SUPJJ
SV3
TEORI
TUS
UB1
V8K
W8V
W99
WBKPD
WIH
WIJ
WIK
WNSPC
WOHZO
WOW
WQJ
WRC
WXI
WXSBR
WYISQ
XG1
~IA
~KM
~WT
AAYXX
AGHNM
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
1OB
7X8
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
ID FETCH-LOGICAL-c3554-18874f1d3f5d659b772dcb64fddf656ac688b02a5af74cb44e7e2d8d93547ab33
IEDL.DBID DR2
ISSN 1747-0277
1747-0285
IngestDate Sun Aug 24 03:59:44 EDT 2025
Thu Apr 03 07:00:35 EDT 2025
Tue Jul 01 04:25:20 EDT 2025
Thu Apr 24 23:03:13 EDT 2025
Wed Jan 22 16:45:54 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords nitrogen-containing bisphosphonates
farnesyl pyrophosphate synthase
three-dimensional quantitative structure-activity relationship
molecular docking
ONIOM
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2017 John Wiley & Sons A/S.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3554-18874f1d3f5d659b772dcb64fddf656ac688b02a5af74cb44e7e2d8d93547ab33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-9704-8435
PMID 29080272
PQID 1957486570
PQPubID 23479
PageCount 12
ParticipantIDs proquest_miscellaneous_1957486570
pubmed_primary_29080272
crossref_primary_10_1111_cbdd_13134
crossref_citationtrail_10_1111_cbdd_13134
wiley_primary_10_1111_cbdd_13134_CBDD13134
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate March 2018
PublicationDateYYYYMMDD 2018-03-01
PublicationDate_xml – month: 03
  year: 2018
  text: March 2018
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Chemical biology & drug design
PublicationTitleAlternate Chem Biol Drug Des
PublicationYear 2018
References 2015; 56
2009; 84
2017; 60
2013; 27
2010
2004; 47
2008; 18
2008; 19
2004; 9
2004; 3
2007; 92
2007; 50
2011; 12
2011; 78
1997; 2
2006; 1
2005; 48
2008; 51
2012; 79
2011; 18
2012; 55
2007; 13
2004; 279
2013; 16
2000; 289
2015; 115
2006; 65
2013; 56
2015; 86
2002; 45
2003; 46
1996; 271
2013; 81
2009; 8
2013; 135
1988; 110
2015; 119
2011; 48
2011; 49
1998; 102
2014; 11
2012; 20
2006; 103
e_1_2_7_5_1
e_1_2_7_3_1
e_1_2_7_9_1
e_1_2_7_7_1
e_1_2_7_17_1
e_1_2_7_15_1
e_1_2_7_41_1
e_1_2_7_13_1
e_1_2_7_11_1
e_1_2_7_45_1
e_1_2_7_47_1
e_1_2_7_26_1
e_1_2_7_49_1
e_1_2_7_28_1
K‐M Chen C. (e_1_2_7_22_1) 2008; 51
e_1_2_7_50_1
e_1_2_7_25_1
e_1_2_7_31_1
e_1_2_7_23_1
e_1_2_7_33_1
Dougherty D. A. (e_1_2_7_46_1) 2013; 16
Kirkpatrick P. (e_1_2_7_43_1) 2004; 3
e_1_2_7_21_1
e_1_2_7_35_1
e_1_2_7_37_1
e_1_2_7_39_1
e_1_2_7_6_1
e_1_2_7_4_1
e_1_2_7_8_1
e_1_2_7_18_1
e_1_2_7_16_1
e_1_2_7_40_1
e_1_2_7_2_1
e_1_2_7_14_1
e_1_2_7_42_1
e_1_2_7_12_1
e_1_2_7_44_1
Prokopenko V. (e_1_2_7_19_1) 2014; 11
e_1_2_7_10_1
e_1_2_7_48_1
e_1_2_7_27_1
Accelrys Software Inc. (e_1_2_7_32_1) 2010
e_1_2_7_29_1
Wang J. (e_1_2_7_38_1) 2004; 9
e_1_2_7_30_1
e_1_2_7_24_1
e_1_2_7_34_1
e_1_2_7_20_1
e_1_2_7_36_1
References_xml – volume: 19
  start-page: 733
  year: 2008
  publication-title: Osteoporos. Int.
– volume: 51
  start-page: 2187
  year: 2008
  publication-title: J. Med. Chem.
– volume: 11
  start-page: 133
  year: 2014
  publication-title: Curr. Drug Discov. Technol.
– volume: 84
  start-page: 632
  year: 2009
  publication-title: Mayo Clin. Proc.
– volume: 20
  start-page: 5583
  year: 2012
  publication-title: Bioorgan. Med. Chem.
– volume: 119
  start-page: 12771
  year: 2015
  publication-title: J. Phys. Chem. B
– volume: 12
  start-page: 397
  year: 2011
  publication-title: Biogerontology
– volume: 48
  start-page: 259
  year: 2011
  publication-title: Bone
– volume: 110
  start-page: 5959
  year: 1988
  publication-title: J. Am. Chem. Soc.
– volume: 49
  start-page: 20
  year: 2011
  publication-title: Bone
– volume: 27
  start-page: 739
  year: 2013
  publication-title: Comput. Aid. Mol. Des.
– volume: 18
  start-page: 2878
  year: 2008
  publication-title: Bioorg. Med. Chem. Lett.
– volume: 9
  start-page: 1157
  year: 2004
  publication-title: J. Comput. Chem.
– volume: 135
  start-page: 5740
  year: 2013
  publication-title: J. Am. Chem. Soc.
– volume: 2
  start-page: 457
  year: 1997
  publication-title: Drug Discov. Today
– volume: 115
  start-page: 5678
  year: 2015
  publication-title: Chem. Rev.
– volume: 289
  start-page: 1508
  year: 2000
  publication-title: Science
– volume: 56
  start-page: 1313
  year: 2015
  publication-title: J. Struct. Chem.
– volume: 103
  start-page: 7829
  year: 2006
  publication-title: Proc. Natl Acad. Sci. USA
– volume: 13
  start-page: 3476
  year: 2007
  publication-title: Curr. Pharm. Des.
– volume: 8
  start-page: 96
  year: 2009
  publication-title: Hormones
– volume: 271
  start-page: 163
  year: 1996
  publication-title: Science
– volume: 1
  start-page: 267
  year: 2006
  publication-title: Chem. Med. Chem.
– year: 2010
– volume: 65
  start-page: 712
  year: 2006
  publication-title: Proteins
– volume: 60
  start-page: 2287
  year: 2017
  publication-title: J. Med. Chem.
– volume: 48
  start-page: 3130
  year: 2005
  publication-title: J. Med. Chem.
– volume: 3
  start-page: 299
  year: 2004
  publication-title: Nat. Rev. Drug Discov.
– volume: 50
  start-page: 5967
  year: 2007
  publication-title: J. Med. Chem.
– volume: 86
  start-page: 731
  year: 2015
  publication-title: Chem. Biol. Drug Des.
– volume: 18
  start-page: 220
  year: 2011
  publication-title: Curr. Med. Chem.
– volume: 56
  start-page: 7939
  year: 2013
  publication-title: J. Med. Chem.
– volume: 51
  start-page: 6800
  year: 2008
  publication-title: J. Med. Chem.
– volume: 55
  start-page: 3201
  year: 2012
  publication-title: J. Med. Chem.
– volume: 78
  start-page: 323
  year: 2011
  publication-title: Chem. Biol. Drug Des.
– volume: 47
  start-page: 375
  year: 2004
  publication-title: J. Med. Chem.
– volume: 102
  start-page: 3762
  year: 1998
  publication-title: J. Phys. Chem. A
– volume: 79
  start-page: 53
  year: 2012
  publication-title: Chem. Biol. Drug Des.
– volume: 46
  start-page: 2932
  year: 2003
  publication-title: J. Med. Chem.
– volume: 279
  start-page: 8526
  year: 2004
  publication-title: J. Biol. Chem.
– volume: 51
  start-page: 5594
  year: 2008
  publication-title: J. Med. Chem.
– volume: 46
  start-page: 5171
  year: 2003
  publication-title: J. Med. Chem.
– volume: 45
  start-page: 2894
  year: 2002
  publication-title: J. Med. Chem.
– volume: 13
  start-page: 1173
  year: 2007
  publication-title: J. Mol. Model.
– volume: 92
  start-page: 3817
  year: 2007
  publication-title: Biophys. J .
– volume: 16
  start-page: 885
  year: 2013
  publication-title: Acc. Chem. Res.
– volume: 48
  start-page: 6128
  year: 2005
  publication-title: J. Med. Chem.
– volume: 81
  start-page: 742
  year: 2013
  publication-title: Chem. Biol. Drug Des.
– ident: e_1_2_7_34_1
  doi: 10.1021/cr5004419
– volume: 51
  start-page: 5594
  year: 2008
  ident: e_1_2_7_22_1
  publication-title: J. Med. Chem.
  doi: 10.1021/jm800325y
– volume: 11
  start-page: 133
  year: 2014
  ident: e_1_2_7_19_1
  publication-title: Curr. Drug Discov. Technol.
  doi: 10.2174/15701638113106660041
– volume: 9
  start-page: 1157
  year: 2004
  ident: e_1_2_7_38_1
  publication-title: J. Comput. Chem.
  doi: 10.1002/jcc.20035
– ident: e_1_2_7_39_1
  doi: 10.1529/biophysj.106.097782
– ident: e_1_2_7_40_1
  doi: 10.1016/S1359-6446(97)01079-9
– ident: e_1_2_7_24_1
  doi: 10.1007/s10822-013-9674-2
– ident: e_1_2_7_30_1
  doi: 10.1016/j.bmc.2012.07.019
– ident: e_1_2_7_42_1
  doi: 10.1021/jp980230o
– ident: e_1_2_7_41_1
  doi: 10.1111/j.1747-0285.2011.01168.x
– ident: e_1_2_7_10_1
  doi: 10.1111/j.1747-0285.2011.01164.x
– ident: e_1_2_7_16_1
  doi: 10.1021/jm058220g
– ident: e_1_2_7_49_1
  doi: 10.1021/acs.jpcb.5b05897
– ident: e_1_2_7_50_1
  doi: 10.1074/jbc.C300511200
– ident: e_1_2_7_48_1
  doi: 10.1021/cr5004419
– ident: e_1_2_7_44_1
  doi: 10.2174/138161207782794284
– ident: e_1_2_7_23_1
  doi: 10.1021/jm0303709
– ident: e_1_2_7_7_1
  doi: 10.1007/s10522-011-9344-5
– ident: e_1_2_7_13_1
  doi: 10.2174/092986711794088335
– ident: e_1_2_7_4_1
  doi: 10.1021/jm0702884
– ident: e_1_2_7_33_1
  doi: 10.1021/ja00226a005
– ident: e_1_2_7_15_1
  doi: 10.1111/cbdd.12545
– ident: e_1_2_7_14_1
  doi: 10.1021/acs.jmedchem.6b01578
– ident: e_1_2_7_2_1
  doi: 10.1007/s00198-007-0540-8
– ident: e_1_2_7_36_1
  doi: 10.1007/s00894-007-0233-4
– volume: 3
  start-page: 299
  year: 2004
  ident: e_1_2_7_43_1
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd1364
– ident: e_1_2_7_9_1
  doi: 10.1021/jm7015733
– ident: e_1_2_7_5_1
  doi: 10.1021/jm400946f
– ident: e_1_2_7_11_1
  doi: 10.1111/cbdd.12121
– ident: e_1_2_7_35_1
  doi: 10.1134/S0022476615070124
– ident: e_1_2_7_17_1
  doi: 10.1021/jm010279
– ident: e_1_2_7_20_1
  doi: 10.1021/jm040132t
– ident: e_1_2_7_21_1
  doi: 10.1021/jm030054u
– ident: e_1_2_7_25_1
  doi: 10.4065/84.7.632
– ident: e_1_2_7_31_1
  doi: 10.1016/j.bone.2011.03.774
– ident: e_1_2_7_6_1
  doi: 10.1002/cmdc.200500059
– volume: 16
  start-page: 885
  year: 2013
  ident: e_1_2_7_46_1
  publication-title: Acc. Chem. Res.
  doi: 10.1021/ar300265y
– ident: e_1_2_7_47_1
  doi: 10.1126/science.271.5246.163
– ident: e_1_2_7_28_1
  doi: 10.1016/j.bmcl.2008.03.088
– ident: e_1_2_7_27_1
  doi: 10.1021/jm801003y
– ident: e_1_2_7_29_1
  doi: 10.1021/jm201657x
– ident: e_1_2_7_45_1
  doi: 10.1021/ja312656v
– ident: e_1_2_7_8_1
  doi: 10.1016/j.bone.2010.09.035
– ident: e_1_2_7_12_1
  doi: 10.1073/pnas.0601643103
– ident: e_1_2_7_3_1
  doi: 10.1126/science.289.5484.1508
– ident: e_1_2_7_18_1
  doi: 10.1021/jm0302344
– ident: e_1_2_7_37_1
  doi: 10.1002/prot.21123
– ident: e_1_2_7_26_1
  doi: 10.14310/horm.2002.1226
– volume-title: Accelrys Discovery Studio, version 3.0
  year: 2010
  ident: e_1_2_7_32_1
SSID ssj0044528
Score 2.217464
Snippet Nitrogen‐containing bisphosphonates (N‐BPs) have been used widely to treat various bone diseases by inhibiting the key enzyme farnesyl pyrophosphate synthase...
Nitrogen-containing bisphosphonates (N-BPs) have been used widely to treat various bone diseases by inhibiting the key enzyme farnesyl pyrophosphate synthase...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 735
SubjectTerms Diphosphonates - chemistry
Enzyme Inhibitors - chemistry
farnesyl pyrophosphate synthase
Geranyltranstransferase - antagonists & inhibitors
Geranyltranstransferase - chemistry
Humans
Hydrogen Bonding
molecular docking
Molecular Docking Simulation
nitrogen‐containing bisphosphonates
ONIOM
Structure-Activity Relationship
three‐dimensional quantitative structure–activity relationship
Title 3D‐QSAR, molecular docking, and ONIOM studies on the structure–activity relationships and action mechanism of nitrogen‐containing bisphosphonates
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcbdd.13134
https://www.ncbi.nlm.nih.gov/pubmed/29080272
https://www.proquest.com/docview/1957486570
Volume 91
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwEB1V5QAXKJ9dWiojuICa1Sax40TqZT9YFaS2olCpFxTZcayuYJPVpnvh1J9QiQP_r7-kM_ZmoYCQ4BApSpw4sWfsl_jNG4CXQsjSCi0CGWYqIPW7QIueDTLdk4iutY6dzuzBYbJ_wt-ditM12GtjYbw-xOqHG3mGG6_JwZVufnLyQhvTDeMwJjFQImsRIjpeaUdxLlxiVUTc0i1ULrVJicbz49Kbs9FvEPMmYnVTzvgefGof1jNNPncX57pbfP1Fx_F_32YD7i6xKOt747kPa2X1AG4P2xRwD-F7PLq6uHz_oX-8y6ZtHl1mcAjFCW-Xqcqwo8O3Rwes8WxEVlcMASXzorSLeXl18Y0CJyg_BZu3tLuzyaxx1_qYCjYtKfp40kxZbRmOMPMajRrrJRa9z1_B9KSZndW0VYSNH8HJ-M3H4X6wzOQQFIRnghCHMm5DE1thEpFphPSm0Am3xlgElKpI0lT3IiWUlbzQnJeyjExqslhwqXQcP4b1qq7KTWA9lYkoMdbiKR6FOiW9IolHEPrYVKYdeNX2aF4sZc4p28aXvP3coabOXVN34MWq7MyLe_yx1PPWMHJsf1pQUVVZL5o8zITkKZGHOvDEW8zqPlFGUcwy6sBr1-9_qSAfDkYjt_f0XwpvwR1Eb6knxG3DOnZt-QwR0rnegVv9wWgw3nEecQ3NCxEb
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwELaqcigX_n-WXyPgAGpWm8SOkwOHsqHapd2tKK3UW4hjW13BJqtNVwhOfQQkDjwFr8JD9EmYsZOFAkLi0AOHSFHixNF4xvPZmfmGkEecC2245J7wk9xD9jtP8p7xEtkTgK6lDC3P7GgcDfbZywN-sEK-trkwjh9iueGGlmHnazRw3JD-ycoLqVTXD_2QNTGVW_rDe1ix1c-GKQzv4yDYfLHXH3hNUQGvQNfq-WBVzPgqNFxFPJGALlUhI2aUMoBt8iKKY9kLcp4bwQrJmBY6ULFKQs5ELnH_E2b8c1hCHKn6090lWxVj3JZyBYwv7K_Rhg0VA4d-fOtp__cbqD2Nka2T27xIvrXicbEtb7uLI9ktPv7CHPnfyO8SudDAbbrh7OMyWdHlFbLWb6vcXSVfwvTk-NOr1xu763TalgqmCrwE-PR1mpeK7oyHOyNau4BLWpUUMDN1vLuLuT45_oy5IViCg87byMLDyay2z7q0ETrVmGA9qae0MhQm0XkFdgv9YqKAK9FB5aSeHVZ4lAj_r5H9M5HLdbJaVqW-SWgvT3gQKWPgFgt8GSMlk4ArgO5MLOIOedKqUFY0TO5YUORd1q7ocGgzO7Qd8nDZdub4S_7Y6kGriRnIH_8Z5aWuFnXmJ1ywGOOjOuSGU9Hle4IEE7VF0CFPraL9pYOs_zxN7dmtf2l8n6wN9kbb2fZwvHWbnAewGrv4vztkFYZZ3wVAeCTvWTOk5M1Z6-131_9uVw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwELaqIgGX8k-XXyPgAGpW-bHj5MChbFh1Kd1CaaXeQhzb6go2WW26QnDqIyBx4CV4FV6iT8KMvVkoICQOPXCIFCVOHI1nPJ-dmW8IecC50IZL7okgLTxkv_Mk942XSl8AupYysjyzW8N4Y4893-f7S-Rrmwvj-CEWG25oGXa-RgOfKPOTkZdSqW4QBRGbh1Ru6g_vYcHWPBlkMLoPw7D_bLe34c1rCnglelYvAKNiJlCR4SrmqQRwqUoZM6OUAWhTlHGSSD8seGEEKyVjWuhQJSqNOBOFxO1PmPDPsNhPsVBEtrMgq2KM20quAPGF_TM6J0PFuKEf33rS_f2GaU9CZOvj-hfIt1Y6LrTlbXd2KLvlx1-II_8X8V0kK3OwTdeddVwiS7q6TM712hp3V8iXKDs--vTq9frOGh23hYKpAh8BHn2NFpWi28PB9hZtXLglrSsKiJk61t3ZVB8ffcbMECzAQadtXOHBaNLYZ13SCB1rTK8eNWNaGwpT6LQGq4V-MU3AFeigctRMDmo8KgT_V8neqcjlGlmu6kqvEuoXKQ9jZQzcYmEgEyRkEnAFsJ1JRNIhj1oNyss5jzuWE3mXt-s5HNrcDm2H3F-0nTj2kj-2utcqYg7yxz9GRaXrWZMHKRcsweioDrnuNHTxnjDFNG0Rdshjq2d_6SDvPc0ye3bjXxrfJWdfZv38xWC4eZOcB6SauOC_W2QZRlnfBjR4KO9YI6TkzWmr7XcYDm0G
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=3D%E2%80%90QSAR%2C+molecular+docking%2C+and+ONIOM+studies+on+the+structure%E2%80%93activity+relationships+and+action+mechanism+of+nitrogen%E2%80%90containing+bisphosphonates&rft.jtitle=Chemical+biology+%26+drug+design&rft.au=Liu%2C+Qing%E2%80%90Zhu&rft.au=Wang%2C+Shan%E2%80%90Shan&rft.au=Li%2C+Xi&rft.au=Zhao%2C+Xue%E2%80%90Yu&rft.date=2018-03-01&rft.issn=1747-0277&rft.eissn=1747-0285&rft.volume=91&rft.issue=3&rft.spage=735&rft.epage=746&rft_id=info:doi/10.1111%2Fcbdd.13134&rft.externalDBID=10.1111%252Fcbdd.13134&rft.externalDocID=CBDD13134
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1747-0277&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1747-0277&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1747-0277&client=summon